Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epstein-Barr virus nuclear antigen 3A (EBNA-3A) is a latent viral protein encoded by the Epstein-Barr virus (EBV) that plays an essential role in the immortalization and continuous proliferation of primary human B lymphocytes. As a key transcriptional regulator, EBNA-3A does not bind DNA directly but is tethered to host genomic sites through interactions with cellular transcription factors such as RBP-Jk (CBF1) and BATF complexes. It cooperates with other EBV latent proteins, particularly EBNA-3C, to epigenetically silence tumor suppressor genes and cell cycle inhibitors, including CDKN2A (p16INK4a/p14ARF), CDKN1A (p21WAF1/CIP1), and BCL2L11 (Bim), thereby preventing apoptosis and senescence. EBNA-3A is strongly implicated in the pathogenesis of EBV-associated malignancies, such as Burkitt's lymphoma, Hodgkin's lymphoma, and post-transplant lymphoproliferative disorders (PTLD). While there are currently no approved small molecules that directly bind and inhibit EBNA-3A, therapeutic strategies under investigation target its downstream epigenetic and survival pathways using EZH2 inhibitors, DNA methyltransferase inhibitors, HDAC inhibitors, and proteasome inhibitors.
No approved drugs directly target EBNA-3A. Experimental strategies focus on inhibiting downstream epigenetic silencing (e.g., using EZH2 inhibitors like GSK126, DNA methyltransferase inhibitors like 5-azacytidine, or HDAC inhibitors like vorinostat) or inducing proteasomal degradation of viral/cellular survival factors (e.g., using bortezomib).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epstein-Barr virus nuclear antigen 3A (EBNA-3A).